Stifel Downgrades Vitae Pharmaceuticals (VTAE) to Hold Amid Takeover

September 14, 2016 10:50 AM EDT
Get Alerts VTAE Hot Sheet
Price: $21.00 --0%

Rating Summary:
    1 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade VTAE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Stifel downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Buy to Hold with a price target of $21.00 after the company agreed to be acquired by Allergan for $639 million.

For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.

Shares of Vitae Pharmaceuticals closed at $8.10 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Downgrades

Related Entities

Stifel

Add Your Comment